d01f4531-b145-414b-bc1c-0f1a148b771e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- MYC_TARGETS_V1+0.400
- PROTEIN_SECRETION+0.400
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V2+0.300
- FATTY_ACID_METABOLISM+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- APICAL_JUNCTION-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- COAGULATION-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.300
- MYOGENESIS-0.300
- NOTCH_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 88328 | EPN | Supratentorial EPN | 0.885 |
| 2 | R135 | — | — | 0.875 |
| 3 | SRR11296797 | — | — | 0.869 |
| 4 | SRR6013515 | — | cohortA4 | 0.854 |
| 5 | TCGA-A8-A081-01A-11R-A00Z-07 | — | C | 0.853 |
| 6 | TCGA-ZF-A9RN-01A-11R-A42T-07 | — | — | 0.851 |
| 7 | e0b0b87d-1125-4834-8133-5d719f1fd255 | — | — | 0.850 |
| 8 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.843 |
| 9 | SRR1797282 | — | cohortSC | 0.842 |
| 10 | SRR11296733 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |